Kornimate/medical-research-clean huggingface dataset:
the influence of paracentesis on intra-abdominal pressure and kidney function in critically ill patients with liver cirrhosis and ascites: an observational study

Conditions: Critically Ill; Liver Cirrhosis; Ascites

Summary: patients with liver cirrhosis are at risk for development of renal failure, usually after a precipitating event such as infection or bleeding. this form of renal failure has a high morbidity and mortality and may be partly caused by increased intra-abdominal pressure secondary to ascites. recent studies have shown that paracentesis (and the resulting decreased iap) can increase urinary output and decrease renal arterial resistive index in patients with hepatorenal syndrome (a very pronounced form of renal failure in cirrhosis patients). the aim of this study is to evaluate the influence of paracentesis on intra-abdominal pressure and kidney function in critically ill patients with liver cirrhosis and ascites across a wider range of kidney function. kidney function will be evaluated using several estimates of glomerular filtration rate and measures of kidney injury i.e. cystatin c, serum ngal, creatinine clearance, urinary output and renal arterial resistive index.


Eligibility criteria:
inclusion criteria: * \>18 y old * admitted to the icu * known liver cirrhosis with ascites on clinical examination and/or ultrasound * sedated and mechanically ventilated * paracentesis deemed necessary by treating physician * arterial and central venous catheter in place * urinary catheter in place exclusion criteria: * previous inclusion in the same study * renal replacement therapy in place * urinary catheter contra-indicated * use of radiocontrast media within 72h before paracentesis

Keywords: critically ill patients liver cirrhosis ascites requiring paracentesis
serologic response to porcine circovirus type 1 (pcv-1) in infants following administration of rotarix™

Conditions: Infections, Rotavirus

Summary: this study aims to evaluate the serologic response to pcv-1 in the serum samples previously collected during initiation of vaccination series of human rotavirus (hrv) vaccine studies (1-2 months post dose 2 of hrv vaccine or placebo). additionally, pre-vaccination sera samples from any infants testing positive for pcv-1 antibodies at the post-vaccination time point will also be evaluated.

serum samples collected from 6 clinical trials previously conducted for hrv vaccine (rotarix™) are used in this study.

Eligibility criteria:
inclusion criteria: not applicable as no subjects will be actively enrolled in this study, only the sera samples of the subjects who were a part of previously conducted trials will be used for testing. however, the archived serum samples of only those subjects who satisfy the following criteria will be included in this study: * subjects who received two doses of hrv vaccine or placebo and were included in the atp cohort for immunogenicity in the primary studies listed. * subjects for whom their parents or legally acceptable representatives (lars) had agreed that their child or wards blood samples could be used for further research while giving consent for any of the primary studies listed. * subjects who have sufficient residual volume of serum samples at both pre- and post-vaccination time points. exclusion criteria: * not applicable

Keywords: human rotavirus (hrv) vaccine serologic response porcine circovirus type 1 (pcv-1) laboratory evaluations
safety study of hemamax™ (rhuil-12) to treat acute radiation syndrome

Conditions: Hematopoietic Syndrome Due to Acute Radiation Syndrome

Summary: the purpose of this study is to determine whether hemamax is safe and well tolerated to support efficacy under fda's animal rule to reduce the morbidity and mortality associated with the hematopoietic syndrome of acute radiation syndrome.

this is a phase 2 single dose, randomized, double-blind, placebo-controlled, multi center study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of hemamax™ (rhuil-12) in healthy adult male and female subjects considered representative of u.s. population.

Eligibility criteria:
inclusion criteria: male and female healthy subjects who have signed the informed consent form must meet all of the following criteria * ≥18 to ≤75 years of age * body mass index (bmi) ≥ 18 and ≤ 35 kg/m2 * normal ecg, vital signs and laboratory test results * use of effective birth control method and abstinence from sex * negative pregnancy test and drug screen exclusion criteria: subjects with any of the following characteristics will be considered ineligible: * history of clinically significant renal, hepatic pulmonary, cardiovascular, cerebrovascular, gastrointestinal, metabolic, hematological, endocrine, urological, immunological, neurologic or psychiatric disorders or connective tissue disease * positive for human immunodeficiency virus (hiv), hepatitis b, or surface antigen (hbsag) or hepatitis c antibody, tuberculosis (tb) * drug or alcohol addiction * history of clinically significant allergy of any kind * prior use of il-12 or hemamax * use of any approved or investigational biologic agents or vaccinations of any kind in last 3 months

Keywords: hemamax, nm-il-12, hsars, safety
il- 6 gene (174g/c) single nucleotide polymorphism as an indicator of covid-19 severity in egyptian patients

Conditions: Covid19

Summary: although the direct damage from the viruses contributes to the initiation of the disease, the cytokine storm caused by covid-19 plays a vital role in the development of acute lung injury and adult respiratory distress syndrome. il-6, a kind of pleiotropic cytokine, is expressed by immune cells such as dc, monocytes, macrophages, b cells, and subsets of activated t cells, as well as by non-immune cells like fibroblasts, epithelial cells, and keratinocytes

the world health organization (who) declared coronavirus disease 2019 (covid-19) a public health emergency of international concern the epidemic has put public health systems under severe strain both in western countries and in the developing world. sars-cov-2 displays a more efficient transmission pattern when compared with sars-cov and mers-cov. although the direct damage from the viruses contributes to the initiation of the disease, the cytokine storm caused by covid-19 plays a vital role in the development of acute lung injury and adult respiratory distress syndrome. il-6, a kind of pleiotropic cytokine, is expressed by immune cells such as dc, monocytes, macrophages, b cells, and subsets of activated t cells, as well as by non-immune cells like fibroblasts, epithelial cells, and keratinocytes. it contributes to the pathogenesis of inflammatory or autoimmunity diseases. excessive production of il-6 leads to serious disease progression in viral infection. the il-6 gene is located on chromosome 7 and several polymorphisms have been reported. the most frequently studied polymorphism is the single nucleotide polymorphism (snp) 174c and - 174g in the promoter region, which has been associated with transcription rates of il6. the incidence of il-6-174c alleles is approximately 40%among the general population. the g allele 174 snp is coupled with the increased transcription upon endotoxin and il-1β stimulation, il-6 -174c allele carrier status is associated with higher level of il-6 production and more severe forms of 4 pneumonia in general. this analysis strengthens the notion that il-6 plays a pivotal role in novel coronavirus pneumonia (ncp) progression, it was il-6-174 c allele rather than g allele that contributed to the risk of sepsis induced by pneumonia

Eligibility criteria:
inclusion criteria: * patients proved to be covid-19 positive * clinical correlation with positive pcr. * clinical correlation with positive rapid antigen detection test. exclusion criteria: * patients with chronic infections including hepatitis b or c infection. * immunodeficiency virus (hiv) infections. * autoimmune diseases including systemic lupus erthromatosus and rheumatoid arthritis. * any malignancy or chronic inflammation * any other chest diseases (tb)
effectiveness of therapeutic exercise on the gut microbiome in chronic widespread pain patients.

Conditions: Arthritis; Fibromyalgia; Arthritis Rheumatoid; Artrosis of the Knee; Chronic Pain; Central Sensitisation; Gut Microbiota; Exercise Therapy

Summary: this study aims to evaluate the effect of therapeutic exercise on the gut microbiome in chronic widespread pain patients. our investigation purpose is to improve the quality of life of participants, reduce their disability and optimize their functionality. the intervention will last 6 weeks, with 2 face-to-face therapeutic exercise sessions guided by a professional and a 6-week post-intervention follow-up. the participation will require: 1. attend the 12 therapeutic exercise sessions 2. attend the 3 evaluations: at the beginning (a0), post intervention (a1) and +6 weeks after finishing the exercise program (a3). the items to be evaluated will be the following: 1. the ronald morris disability questionnaire (rmdq) 2. anxiety (state-trait anxiety inventory (stai)) 3. depression: beck depression inventory (bdi) 4. quality of life: sf-12 5. pain: numerical scale (0-100) and the brief pain inventory (bpi) 6. sensory tests: heat pain threshold (hpt), pressure pain threshold (ppt) and pain modulation (cpm) 7. perform a pre blood test on interleukins il-18 and il-1β this study involves the processing of personal data, so the researchers will guarantee confidentiality in their treatment at all times, complying with the personal data protection regulations, in particular, european regulation 679/2016. , of april 27, general data protection, as well as organic law 3/2018, of december 5, protection of personal data and guarantee of digital rights. in order to maintain your privacy and anonymity during the research, only one person on the research team will know how names were assigned to a participation number.


Eligibility criteria:
inclusion criteria: * patients must be at least 18 years old * must be diagnosed with: osteoarthritis, osteoarthritis, sudeck or fibromyalgia. exclusion criteria: * suffering or having suffered from cancer, psychiatric disorders, or another ongoing major illness (irritable bowel syndrome, hepatitis, lyme disease or diabetes). * patients will be excluded if they have more than 6 points on the beck depression inventory, more than 30 points on the "state trait anxiety inventory" or suffer from dementia.
suprachoroidal injection of triamcinolone acetonide using custom made needle to treat retinal disorders

Conditions: Diabetic Macular Edema, Cystoid Macular Edema, Chorodial Neovascularzation, Posterior Uveitis

Summary: injection in the suprachoroidal space has potential of increasing the efficacy of the drug upto six times with direct effect on retinal tissues sparing the crystalline lens and trabecular meshwork.

a custom made 30 gauge needle offering 1000 micron penetration of the sclera at the parsplana with the help of gentle pressure on the sclera will help to inject medication such as triamcinilone or vegf blockade agents (ziv aflibercept or bevacizumab) in the potential suprachoroidal space which offers direct effect of injected drug on the retina and choroid sparing both crystalline lens, trabecular meshwork and other ocular tissues, hence improving efficacy of the drug upto six times and reduce potential complications such as cataract and glaucoma.

Eligibility criteria:
inclusion criteria: * 20 years and older * patients with macular edema or degeneration from various pathologies * central macular thickness more than 250 microns * patients who are able to come for all follow-up exclusion criteria: * significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant. * myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization * for women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 3 years. * exam evidence of severe external ocular infection, including conjunctivitis, chalazion, or substantial blepharitis
phase 3 study of dw-330sr2 and pelubiprofen in chronic back pain patients

Conditions: Chronic Back Pain

Summary: a multicenter, randomized, double-blinded, parallel, active-controlled, phase iii clinical trial to evaluate the efficacy and safety of dw-330sr2 and pelubiprofen in chronic back pain patients.


Eligibility criteria:
inclusion criteria: * more than 12 weeks by the time the trial started , and low back pain that requires analgesia administration. * class 1 or 2 back pain patients along quebec task force classification * patients with pain at least 40mm test results at visit2 * the voluntary or legal guardian 's written consent to participate in this clinical trial subjects exclusion criteria: * severe gastrointestinal disease, heart disease, high blood pressure patients * patients with secondary causes are obvious * within 24 weeks patient who has back surgery before clinical trial participation * within 4 weeks patient who experienced psychotropic drugs, a narcotic analgesic dosage that may affect the pain sensation * within 4 weeks patient who treated steroid drug by oral or injection * within 2 weeks patient who treated mao inhibition drugs * patients with severe respiratory depression status
clinical study on improving exercise capacity in chronic obstructive pulmonary disease through smart iot-remote home breathing guidance

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study aims to evaluate the clinical efficacy of breath-guided improvement of copd exercise ability, establish a breath-guided rehabilitation program of intelligent iot and remote home, improve copd exercise ability, reduce acute exacerbation, and form high-quality clinical evidence.

chronic obstructive pulmonary disease (copd) is the most common chronic airway disease in china. based on the digital management platform, 548 patients with copd in stable stage were selected as the research objects. a multi-center, randomized, controlled clinical trial design was adopted to scientifically evaluate the clinical efficacy of breath-guided improvement of copd exercise ability and reveal its mechanism of action. a breath-guided rehabilitation program based on intelligent iot and remote home was established and promoted to improve exercise ability and reduce acute exacerbation. to form high-quality clinical evidence, and realize tracking management, real-time evaluation and effect evaluation throughout rehabilitation.

Eligibility criteria:
inclusion criteria: * patients with copd in stable stage * patients with grade 2 to 4 lung function * age 40\~80 years old * be able to use smart phones, computers and other devices independently or with the help of family members during home training * volunteer for treatment and sign an informed consent form exclusion criteria: * pregnant or lactating women and patients with recent pregnancy plans * delirious, dementia, all kinds of mental illness * tumor patients who have undergone resection, radiation, and chemotherapy within 5 years * patients with severe osteoarthropathy or osteoporosis, unstable fractures * patients with severe visual impairment that cannot be improved or who have epilepsy or vertigo and cannot use vr devices * patients with progressive neuromuscular disease * patients with pulmonary abscess, pulmonary interstitial fibrosis, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism and other pulmonary diseases * patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, grade 3 or above cardiac function, stroke, cerebral hemorrhage, etc.) * patients with severe liver disease (cirrhosis, portal hypertension and bleeding caused by esophageal and gastric varices, etc.) and severe kidney disease (dialysis, kidney transplantation, etc.) * participants who were participating in other clinical trials within 1 month prior to enrollment * people who stay in bed for a long time for various reasons

Keywords: stable stage of chronic obstructive pulmonary disease tele-home rehabilitation randomized controlled trial
thromboembolic complications in mild covid-19 cases

Conditions: COVID 19; Thromboembolic and Bleeding Complications; Thromboembolism, Venous; Post COVID-19

Summary: the aim of the study is to investigate the frequency of thromboembolic complications and the factors influencing them in covid-19 cases that did not require hospitalization. for this purpose, patients registered at two different family health centers in istanbul were retrospectively screened, and their status regarding post-covid-19 thromboembolic events was recorded. the sociodemographic characteristics, medical history, covid-19 treatments received, comorbidities, and current medications of all patients were examined and compared with the occurrence of complications.

studies on covid-19 complications in the literature have predominantly focused on patients treated in hospitals, particularly in intensive care units. data on patients with mild to moderate symptoms who were followed up on an outpatient basis in primary care are quite limited. therefore, our research investigated the incidence of thrombotic events within six months following infection in mild to moderate covid-19 cases and the factors that might influence these events. records of 961 individuals registered at two different family health centers in istanbul were reviewed. patients were contacted by phone, informed about the study, and data regarding their sociodemographic characteristics, medical histories, covid-19 infection experiences, and medications used were collected. comparative analyses (fisher's exact test) and logistic regression tests were conducted.

Eligibility criteria:
inclusion criteria: * being over 18 years of age * having had a confirmed covid-19 infection verified by a pcr test * being monitored at a family health center without requiring hospitalization during the covid-19 course * having at least 6 months elapsed since the infection * availability of the patient's medical records * absence of any language barrier or health issue that would prevent communication with the patient exclusion criteria: * being under 18 years of age * having had less than 6 months since the covid-19 infection * presence of any condition that prevents communication with the patient * incomplete or missing medical records of the patient * history of hospitalization due to covid-19 infection

Keywords: covid 19 thromboembolism thromboembolic complications pulmonary embolism deep venous thrombosis
evaluation of safety, pk, and preliminary effects on scar formation of multiple intradermal administrations of rxi-109

Conditions: Cicatrix; Scar Prevention

Summary: the purpose of this trial is to evaluate the safety and tolerability of multiple (3) intradermal doses of rxi-109 at small surgical incisions in the abdominal skin of healthy volunteers. the effect of rxi-109 versus placebo on scarring at these incision sites will be evaluated visually, histologically, and by biomarker analysis.


Eligibility criteria:
inclusion criteria: * males and females, 21-50 years of age * general good health; if female not pregnant or lactating * phototype 3 and above based on the fitzpatrick scale. exclusion criteria: * pregnant or lactating * use of tobacco or nicotine-containing products within 1 month prior to enrollment and while on study * type 1 or 2 diabetes mellitus * a history or presence of any medical condition or therapy that would make the subject an unsafe candidate in the opinion of the investigator

Keywords: scar scar prevention fibrosis
acute effects of a stretching program of the rib cage muscles on patients with copd during exercise

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: investigate the effects of stretching the muscles of the rib cage in individuals with copd during exercise.

to investigate the effects of a stretching program for the muscles of the rib cage or control in patients with copd during exercise and / or the immediate post-exercise, using the following parameters: * tidal volume (vt), respiratory rate (rr), minute volume (mv), inspiratory time (tins) and expiratory (t exp). * change in volumes of total and regional chest magazines (pulmonary rib cage, abdominal rib cage and abdomen). * diaphragmatic mobility. * electrical muscle activity * endurance time. * dyspnea sensation.

Eligibility criteria:
inclusion criteria: * smoking history, occupational or environmental exposure to pollutants and / or symptoms of cough, dyspnea or hypersecretion; * fev1 \<80% predicted and post-bronchodilator fev1 / fvc \<70% to confirm the diagnosis of airway obstruction not fully reversible bronchodilator therapy; * absence of co-morbidities that does not allow the realization of stress (hypertension, severe pulmonary hypertension, myocardial infarction, congestive heart failure, severe dyspnoea); * preserved cognitive functioning; * sedentary * clinically stable during the study period. exclusion criteria: * patients with cognitive, hearing or visual deficit; * changes in the neuro-musculo-skeletal system which endangers or impairs the assessment; * obese * not be able to achieve at least three stages of the incremental test.
investigation of the relationship of smartphone use time with neck endurance, head posture, lateral grip strength, hand grip strength and postural control parameters in young adults

Conditions: Cell Phone Use

Summary: in the planned study, young adults between the ages of 18-35 with different phone usage durations will be evaluated. the aim of the study is to investigate whether the average daily phone usage time has a direct relationship with neck muscle endurance, rough grip strength, lateral grip strength and head posture, and whether there is an indirect relationship with postural control. people who have phones with ios 12 or android 9 and above will be invited to the study. by looking at the screen time tracking feature in these versions, the daily phone usage hour for the last week will be calculated and the participants will be divided into two groups as the daily phone usage average of 5, and below and 5 hours. in the planned study, neck endurance will be tested on flexor and extensor muscle groups in accordance with the literature. the lateral flexion and anterior tilt angles will be calculated with two photographs taken from the anterior and lateral sides of the head posture of the person's shoulder, and the hand grip strength will be measured with a jamar hand dynamometer and the lateral grip strength will be measured with a pinchmeter. postural control evaluation will be measured by means of center of pressure-cop parameters measured with tekscan brand pressure platform. the study is planned to be carried out in the movement analysis laboratory of the faculty of physical therapy and rehabilitation of dokuz eylul university. participants will be selected from healthy adults between the ages of 18-35 who volunteered to participate in the study among the students of the faculty of physical therapy and rehabilitation, their relatives and the relatives of the researcher. the study is planned to be completed within 6 months following ethical approval.


Eligibility criteria:
inclusion criteria: * using a phone with ios 12 or android 9 and above for at least one week exclusion criteria: * presence of orthopedic surgery in the last 6 months * those who have a disease or take medication that will prevent neuromuscular system and postural control measurements * have neck pain

Keywords: cop balance forehead posture